Acceleris Capital
VC Fund
Manchester, United Kingdom
Acceleris Capital is a VC fund in Manchester focused on Biotechnology and Health Care. Acceleris Capital arrange new capital for SME's and have direct investment in several technology based companies. They serve funding, investment and advisory needs from their office in central Manchester. Their USP is taking companies from startup through to exit, not only adding comfort to their introduced investors, but also providingongoing mentoring and support at the most crucial time of an SMEs lifecycle.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Acceleris Capital invests in
Stages Acceleris Capital invests in
Countries Acceleris Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Venture - Series Unknown
- $1.5M–$4.2M
Investment Focus
Industry
- Biotechnology 5 (31%)
- Health Care 3 (19%)
- Manufacturing 3 (19%)
- Pharmaceutical 3 (19%)
- Farming 2 (13%)
Stage
- Funding Round 6 (38%)
- Seed 4 (25%)
- Venture - Series Unknown 3 (19%)
Country
- United Kingdom 9 (56%)
- Australia 1 (6%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Norman Molyneux
Managing Director
|
Managing Director | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Reacta Healthcare
|
Reacta Healthcare develops diagnostic solutions and challenge meals for food allergy testing and clinical research. | $1.5M / Venture - Series Unknown / Sep 12, 2022 | |
Power Roll
|
Power Roll Limited was established to develop and commercialise its highly innovative proprietary energy storage and energy generation technologies. Power Roll technologies exhibit a range of significant benefits and advantages over existing technologies such that it is likely that the technology can prove extremely disruptive across a wide rangeof applications and markets. Power Roll has a strong intellectual property portfolio, with 15 different patent families already established. These patent families are spread across all three technologies with five directly related to Energy Storage, nine related to Solar PV and one focusing on the nano-barrier technology. | $4.2M / Venture - Series Unknown / Feb 19, 2021 | |
Reacta Biotech
|
Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP). | $1.5M / Venture - Series Unknown / Apr 21, 2020 | |
|
Reacta Healthcare
|
Reacta Healthcare develops diagnostic solutions and challenge meals for food allergy testing and clinical research. | $1.5M / Venture - Series Unknown / Apr 21, 2020 | |
Vertical Future
|
Vertical Future is a technology company focused on building a better, more sustainable urban food production and supply system. | $5.2M / Seed / Oct 08, 2019 | |
ADC Biotechnology
|
ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs. | $7.9M / Sep 25, 2017 | |
Redag Crop Protection
|
The novel and broadly validated Redox Switch™ approach allows Redag Crop Protection to begin with best in class crop protection products and find new intellectual property that supports development of novel agrochemicals. These properties have shorter less costly development cycles bringing rapid innovation to the industry. There is a growing needfor new products as older ones are withdrawn either for safety reasons or because resistance has developed that reduces performance. | $2M / Sep 19, 2017 | |
Apex Molecular
|
Apex Molecular a leading provider of specialist chemistry services to the pharmaceutical, biotechnology and applied chemistry sectors. | Oct 06, 2016 | |
|
Redag Crop Protection
|
The novel and broadly validated Redox Switch™ approach allows Redag Crop Protection to begin with best in class crop protection products and find new intellectual property that supports development of novel agrochemicals. These properties have shorter less costly development cycles bringing rapid innovation to the industry. There is a growing needfor new products as older ones are withdrawn either for safety reasons or because resistance has developed that reduces performance. | $2M / Mar 03, 2016 | |
Evgen Pharma
|
Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers haveidentified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products. | $2M / Sep 10, 2015 | |
| See all 16 investments → | |||
Co-Investors
Development Bank of Wales
4 deals together
Catapult Ventures
1 deal together
Earthworm Group
1 deal together
Enterprise Ventures
1 deal together
GM&C Life Sciences Fund
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Acceleris Capital invest in?
Acceleris Capital invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Funding Round and Seed stage. Most of the 16 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Acceleris Capital's check size?
Acceleris Capital typically joins rounds of $1.5M–$4.2M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Acceleris Capital participates in.
How do I contact Acceleris Capital?
Public channels for Acceleris Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Acceleris Capital?
The team at Acceleris Capital includes Norman Molyneux (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
